{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T13:51:23Z","timestamp":1676814683605},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T00:00:00Z","timestamp":1298419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00108-010-2678-2","type":"journal-article","created":{"date-parts":[[2011,2,21]],"date-time":"2011-02-21T14:04:42Z","timestamp":1298297082000},"page":"250-264","source":"Crossref","is-referenced-by-count":2,"title":["Pr\u00e4vention der Virushepatitis A bis E"],"prefix":"10.1007","volume":"52","author":[{"given":"M.","family":"Cornberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,23]]},"reference":[{"key":"2678_CR1","first-page":"1080","volume":"56","author":"Advisory","year":"2007","unstructured":"Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC) (2007) Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 56:1080\u20131084","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2678_CR2","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.vaccine.2010.03.038","volume":"28","author":"Alavian","year":"2010","unstructured":"Alavian SM, Tabatabaei SV (2010) The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature. Vaccine 28:3773\u20133777","journal-title":"Vaccine"},{"key":"2678_CR3","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1097\/00042560-199802001-00003","volume":"18","author":"Alter","year":"1998","unstructured":"Alter MJ, Moyer LA (1998) The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 18 (Suppl 1):S6\u201310","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"2678_CR4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00007890-200107270-00019","volume":"72","author":"Arslan","year":"2001","unstructured":"Arslan M, Wiesner RH, Poterucha JJ et al (2001) Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 72:272\u2013276","journal-title":"Transplantation"},{"key":"2678_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000149370","volume":"20","author":"Balayan","year":"1983","unstructured":"Balayan MS, Andjaparidze AG, Savinskaya SS et al (1983) Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 20:23\u201331","journal-title":"Intervirology"},{"key":"2678_CR6","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/jmv.21883","volume":"82","author":"Bovier","year":"2010","unstructured":"Bovier PA, Bock J, Ebengo TF et al (2010) Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol 82:1629\u20131634","journal-title":"J Med Virol"},{"key":"2678_CR7","doi-asserted-by":"crossref","unstructured":"Brown RS, Buti M, Goodwin D et al (2009) Hepatitis B virus (HBV) drugs in pregnancy: findings from the antiretroviral pregnancy registry. Columbia University, College of Physicians and Surgeons, New York, NY USA, diane.goodwin@gilead.com","DOI":"10.1016\/S0168-8278(09)60005-2"},{"key":"2678_CR8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","volume":"336","author":"Chang","year":"1997","unstructured":"Chang MH, Chen CJ, Lai MS et al (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855\u20131859","journal-title":"N Engl J Med"},{"key":"2678_CR9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"Choo","year":"1989","unstructured":"Choo QL, Kuo G, Weiner AJ et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359\u2013362","journal-title":"Science"},{"key":"2678_CR10","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.4049\/jimmunol.1001875","volume":"185","author":"Chou","year":"2010","unstructured":"Chou HY, Lin XZ, Pan WY et al (2010) Hydrogel-delivered GM-CSF overcomes nonresponsiveness to hepatitis B vaccine through the recruitment and activation of dendritic cells. J Immunol 185:5468\u20135475","journal-title":"J Immunol"},{"key":"2678_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0264-410X(96)00205-8","volume":"15","author":"Clemens","year":"1997","unstructured":"Clemens R, Sanger R, Kruppenbacher J et al (1997) Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule \u2013 results of a post-marketing surveillance. Vaccine 15:349\u2013352","journal-title":"Vaccine"},{"key":"2678_CR12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0149-2918(01)80044-8","volume":"23","author":"Coates","year":"2001","unstructured":"Coates T, Wilson R, Patrick G et al (2001) Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 23:392\u2013403","journal-title":"Clin Ther"},{"key":"2678_CR13","first-page":"451","volume":"56","author":"Cornberg","year":"2010","unstructured":"Cornberg M, Jaroszewicz J, Manns MP et al (2010) Treatment of chronic hepatitis B. Minerva Gastroenterol Dietol 56:451\u2013465","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2678_CR14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1055\/s-2007-963232","volume":"45","author":"Cornberg","year":"2007","unstructured":"Cornberg M, Protzer U, Dollinger MM et al (2007) Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus- (HBV-) Infection: upgrade of the guideline, AWMF-Register 021\/011. Z Gastroenterol 45:525\u2013574","journal-title":"Z Gastroenterol"},{"key":"2678_CR15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMc0903778","volume":"361","author":"Dalton","year":"2009","unstructured":"Dalton HR, Bendall RP, Keane FE et al (2009) Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 361:1025\u20131027","journal-title":"N Engl J Med"},{"key":"2678_CR16","first-page":"1","volume":"58","author":"Daniels","year":"2009","unstructured":"Daniels D, Grytdal S, Wasley A (2009) Surveillance for acute viral hepatitis \u2013 United States, 2007. MMWR Surveill Summ 58:1\u201327","journal-title":"MMWR Surveill Summ"},{"key":"2678_CR17","doi-asserted-by":"crossref","unstructured":"Fabrizi F, Dixit V, Messa P, Martin P (2010) Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: a meta-analysis of randomized trials. J Viral Hepat [Epub ahead of print]","DOI":"10.1111\/j.1365-2893.2010.01354.x"},{"key":"2678_CR18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2036.2010.04410.x","volume":"32","author":"Fabrizi","year":"2010","unstructured":"Fabrizi F, Dixit V, Messa P, Martin P (2010) Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients. Aliment Pharmacol Ther 32:756\u2013762","journal-title":"Aliment Pharmacol Ther"},{"key":"2678_CR19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1365-2036.2006.03035.x","volume":"24","author":"Fabrizi","year":"2006","unstructured":"Fabrizi F, Ganeshan SV, Dixit V et al (2006) Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 24:789\u2013796","journal-title":"Aliment Pharmacol Ther"},{"key":"2678_CR20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"Fattovich","year":"2008","unstructured":"Fattovich G, Bortolotti F, Donato F (2008) Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48:335\u2013352","journal-title":"J Hepatol"},{"key":"2678_CR21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1086\/381671","volume":"38","author":"Fiore","year":"2004","unstructured":"Fiore AE (2004) Hepatitis A transmitted by food. Clin Infect Dis 38:705\u2013715","journal-title":"Clin Infect Dis"},{"key":"2678_CR22","first-page":"1","volume":"55","author":"Fiore","year":"2006","unstructured":"Fiore AE, Wasley A, Bell BP (2006) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55:1\u201323","journal-title":"MMWR Recomm Rep"},{"key":"2678_CR23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","volume":"125","author":"Gerlach","year":"2003","unstructured":"Gerlach JT, Diepolder HM, Zachoval R et al (2003) Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125:80\u201388","journal-title":"Gastroenterology"},{"key":"2678_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000149367","volume":"20","author":"Gust","year":"1983","unstructured":"Gust ID, Coulepis AG, Feinstone SM et al (1983) Taxonomic classification of hepatitis A virus. Intervirology 20:1\u20137","journal-title":"Intervirology"},{"key":"2678_CR25","doi-asserted-by":"crossref","unstructured":"Hadem J, Wedemeyer H, Manns MP (2004) Hepatitis als Reisekrankheit. Internist (Berl) 45:655\u2013668","DOI":"10.1007\/s00108-004-1197-4"},{"key":"2678_CR26","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1086\/593335","volume":"198","author":"Hammitt","year":"2008","unstructured":"Hammitt LL, Bulkow L, Hennessy TW et al (2008) Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 198:1776\u20131782","journal-title":"J Infect Dis"},{"key":"2678_CR27","doi-asserted-by":"crossref","first-page":"427A","DOI":"10.1002\/hep.23703","volume":"52","author":"Han","year":"2010","unstructured":"Han G, Zhao W, Cao M et al (2010) A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus (HBV) to the infants. Hepatology 52:427A\u2013428A","journal-title":"Hepatology"},{"key":"2678_CR28","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","volume":"360","author":"Hezode","year":"2009","unstructured":"Hezode C, Forestier N, Dusheiko G et al (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360:1839\u20131850","journal-title":"N Engl J Med"},{"key":"2678_CR29","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","volume":"36","author":"Hoofnagle","year":"2002","unstructured":"Hoofnagle JH (2002) Course and outcome of hepatitis C. Hepatology 36:S21\u2013S29","journal-title":"Hepatology"},{"key":"2678_CR30","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1086\/656776","volume":"202","author":"Hwang","year":"2010","unstructured":"Hwang LY, Grimes CZ, Tran TQ et al (2010) Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. J Infect Dis 202:1500\u20131509","journal-title":"J Infect Dis"},{"key":"2678_CR31","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jama.271.17.1328","volume":"271","author":"Innis","year":"1994","unstructured":"Innis BL, Snitbhan R, Kunasol P et al (1994) Protection against hepatitis A by an inactivated vaccine. JAMA 271:1328\u20131334","journal-title":"JAMA"},{"key":"2678_CR32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/00365540110077362","volume":"34","author":"Iwarson","year":"2002","unstructured":"Iwarson S, Lindh M, Widerstrom L (2002) Excellent booster response 4\u20136 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 34:110\u2013111","journal-title":"Scand J Infect Dis"},{"key":"2678_CR33","unstructured":"Jahresstatistik des Robert Koch-Instituts. www.rki.de"},{"key":"2678_CR34","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1055\/s-2008-1065189","volume":"115","author":"Jilg","year":"1990","unstructured":"Jilg W, Schmidt M, Deinhardt F (1990) Inoculation failure following hepatitis B vaccination. The effect of additional vaccinations. Dtsch Med Wochenschr 115:1545\u20131548","journal-title":"Dtsch Med Wochenschr"},{"key":"2678_CR35","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1055\/s-2003-42929","volume":"41","author":"Kallinowski","year":"2003","unstructured":"Kallinowski B, Jilg W, Buchholz L et al (2003) Immunogenicity of an accelerated vaccination regime with a combined hepatitis a\/b vaccine in patients with chronic hepatitis C. Z Gastroenterol 41:983\u2013990","journal-title":"Z Gastroenterol"},{"key":"2678_CR36","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/j.1600-6143.2008.02286.x","volume":"8","author":"Kamar","year":"2008","unstructured":"Kamar N, Mansuy JM, Cointault O et al (2008) Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant 8:1744\u20131748","journal-title":"Am J Transplant"},{"key":"2678_CR37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa0706992","volume":"358","author":"Kamar","year":"2008","unstructured":"Kamar N, Selves J, Mansuy JM et al (2008) Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358:811\u2013817","journal-title":"N Engl J Med"},{"key":"2678_CR38","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hep.510270336","volume":"27","author":"Keeffe","year":"1998","unstructured":"Keeffe EB, Iwarson S, McMahon BJ et al (1998) Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27:881\u2013886","journal-title":"Hepatology"},{"key":"2678_CR39","doi-asserted-by":"crossref","unstructured":"Kubitschke A, Bader C, Tillmann HL et al (2007) Verletzungen mit Hepatitis-C-Virus-kontaminierten Nadeln. Internist (Berl) 48:1165\u20131172","DOI":"10.1007\/s00108-007-1912-z"},{"key":"2678_CR40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"Kwo","year":"2010","unstructured":"Kwo PY, Lawitz EJ, McCone J et al (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705\u2013716","journal-title":"Lancet"},{"key":"2678_CR41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0264-410X(00)00188-2","volume":"19","author":"Landry","year":"2000","unstructured":"Landry P, Tremblay S, Darioli R et al (2000) Inactivated hepatitis A vaccine booster given >\/=24 months after the primary dose. Vaccine 19:399\u2013402","journal-title":"Vaccine"},{"key":"2678_CR42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0168-8278(90)90071-X","volume":"10","author":"Liaw","year":"1990","unstructured":"Liaw YF, Chen TJ, Chu CM et al (1990) Acute hepatitis delta virus superinfection in patients with liver cirrhosis. J Hepatol 10:41\u201345","journal-title":"J Hepatol"},{"key":"2678_CR43","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"Manns","year":"2006","unstructured":"Manns MP, Wedemeyer H, Cornberg M (2006) Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55:1350\u20131359","journal-title":"Gut"},{"key":"2678_CR44","doi-asserted-by":"crossref","unstructured":"Pecoraro ML, Martin JT, Halperin S et al (2009) A phase 3 safety and efficacy study comparing immunogenicity of two doses of HBsAg combined with immunostimulatory sequence with three doses of licensed hepatitis vaccine. Dynavax Technol, Berkeley, CA USA,mpecoraro@dynavax.com","DOI":"10.1016\/S0168-8278(09)61042-4"},{"key":"2678_CR45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"Perz","year":"2006","unstructured":"Perz JF, Armstrong GL, Farrington LA et al (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529\u2013538","journal-title":"J Hepatol"},{"key":"2678_CR46","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1055\/s-0030-1255136","volume":"135","author":"Pischke","year":"2010","unstructured":"Pischke S, Potthoff A, Hauroder B et al (2010) Hepatitis E virus infection: a paradigm shift? Dtsch Med Wochenschr 135:1129\u20131133","journal-title":"Dtsch Med Wochenschr"},{"key":"2678_CR47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/lt.21958","volume":"16","author":"Pischke","year":"2010","unstructured":"Pischke S, Suneetha PV, Baechlein C et al (2010) Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 16:74\u201382","journal-title":"Liver Transpl"},{"key":"2678_CR48","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.vaccine.2009.10.068","volume":"28","author":"Poorolajal","year":"2010","unstructured":"Poorolajal J, Mahmoodi M, Majdzadeh R et al (2010) Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 28:623\u2013631","journal-title":"Vaccine"},{"key":"2678_CR49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","volume":"5","author":"Rehermann","year":"2005","unstructured":"Rehermann B, Nascimbeni M (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5:215\u2013229","journal-title":"Nat Rev Immunol"},{"key":"2678_CR50","unstructured":"Rizzetto M, Verme G (1985) Hepatitis D. Internist (Berl) 26:628\u2013632"},{"key":"2678_CR51","first-page":"383","volume":"50","author":"Robert","year":"2001","unstructured":"Robert Koch-Institut (2001) Zu \u00dcbertragungswegen und \u00dcbertragungsfaktoren der Hepatitis A \u2013 Ergebnisse einer epidemiologischen Untersuchung in Hamburg. Epidemiol Bull 50:383\u2013384","journal-title":"Epidemiol Bull"},{"key":"2678_CR52","first-page":"457","volume":"49","author":"Robert","year":"2007","unstructured":"Robert Koch-Institut (2007) Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2006. Epidemiol Bull 49:457\u2013468","journal-title":"Epidemiol Bull"},{"key":"2678_CR53","first-page":"435","volume":"49","author":"Robert","year":"2008","unstructured":"Robert Koch-Institut (2008) Hepatitis E \u2013 Epidemiologie und Risikofaktoren in Deutschland. Epidemiol Bull 49:435\u2013464","journal-title":"Epidemiol Bull"},{"key":"2678_CR54","first-page":"379","volume":"44","author":"Robert","year":"2008","unstructured":"Robert Koch-Institut (2008) Zur Situation der Hepatitis A in Deutschland im Jahr 2007. Epidemiol Bull 44:379\u2013384","journal-title":"Epidemiol Bull"},{"key":"2678_CR55","first-page":"279","volume":"30","author":"Robert","year":"2010","unstructured":"Robert Koch-Institut (2010) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut\/Stand: Juli 2010. Epidemiol Bull 30:279\u2013298","journal-title":"Epidemiol Bull"},{"key":"2678_CR56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-0028-1110008","volume":"48","author":"Sarrazin","year":"2010","unstructured":"Sarrazin C, Berg T, Ross RS et al (2010) Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 48:289\u2013351","journal-title":"Z Gastroenterol"},{"key":"2678_CR57","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558\u2013567","journal-title":"Lancet Infect Dis"},{"key":"2678_CR58","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa061847","volume":"356","author":"Shrestha","year":"2007","unstructured":"Shrestha MP, Scott RM, Joshi DM et al (2007) Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 356:895\u2013903","journal-title":"N Engl J Med"},{"key":"2678_CR59","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/317489a0","volume":"317","author":"Tiollais","year":"1985","unstructured":"Tiollais P, Pourcel C, Dejean A (1985) The hepatitis B virus. Nature 317:489\u2013495","journal-title":"Nature"},{"key":"2678_CR60","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0140-6736(03)14418-2","volume":"362","author":"Van","year":"2003","unstructured":"Van Damme P, Banatvala J, Fay O et al (2003) Hepatitis A booster vaccination: is there a need? Lancet 362:1065\u20131071","journal-title":"Lancet"},{"key":"2678_CR61","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/505115","volume":"43","author":"Van","year":"2006","unstructured":"Van Effelterre TP, Zink TK, Hoet BJ et al (2006) A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization. Clin Infect Dis 43:158\u2013164","journal-title":"Clin Infect Dis"},{"key":"2678_CR62","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmaid.2006.07.003","volume":"5","author":"Van","year":"2007","unstructured":"Van Herck K, Leroux-Roels G, Van Damme P et al (2007) Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med Infect Dis 5:171\u2013175","journal-title":"Travel Med Infect Dis"},{"key":"2678_CR63","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa070546","volume":"357","author":"Victor","year":"2007","unstructured":"Victor JC, Monto AS, Surdina TY et al (2007) Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 357:1685\u20131694","journal-title":"N Engl J Med"},{"key":"2678_CR64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","volume":"7","author":"Wedemeyer","year":"2010","unstructured":"Wedemeyer H, Manns MP (2010) Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7:31\u201340","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2678_CR65","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199208133270702","volume":"327","author":"Werzberger","year":"1992","unstructured":"Werzberger A, Mensch B, Kuter B et al (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327:453\u2013457","journal-title":"N Engl J Med"},{"key":"2678_CR66","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/jac\/dkn346","volume":"62","author":"Wiegand","year":"2008","unstructured":"Wiegand J, Deterding K, Cornberg M et al (2008) Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 62:860\u2013865","journal-title":"J Antimicrob Chemother"},{"key":"2678_CR67","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/S0264-410X(03)00250-0","volume":"21","author":"Williams","year":"2003","unstructured":"Williams JL, Bruden DA, Cagle HH et al (2003) Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 21:3208\u20133211","journal-title":"Vaccine"},{"key":"2678_CR68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000199735","volume":"35","author":"Wismans","year":"1988","unstructured":"Wismans P, Hattum J van, Stelling T et al (1988) Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination. Hepatogastroenterology 35:78\u201379","journal-title":"Hepatogastroenterology"},{"key":"2678_CR69","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1016\/S0264-410X(03)00399-2","volume":"21","author":"Wolters","year":"2003","unstructured":"Wolters B, Junge U, Dziuba S et al (2003) Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21:3623\u20133628","journal-title":"Vaccine"},{"key":"2678_CR70","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.vaccine.2005.10.049","volume":"24","author":"Woo","year":"2006","unstructured":"Woo EJ, Miller NB, Ball R (2006) Adverse events after hepatitis A B combination vaccine. Vaccine 24:2685\u20132691","journal-title":"Vaccine"},{"key":"2678_CR71","first-page":"33","volume":"26","author":"World","year":"2000","unstructured":"World Health Organization (2000) WHO position paper on hepatitis A vaccines. Can Commun Dis Rep 26:33\u201338","journal-title":"Can Commun Dis Rep"},{"key":"2678_CR72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)61030-6","volume":"376","author":"Zhu","year":"2010","unstructured":"Zhu FC, Zhang J, Zhang XF et al (2010) Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376:895\u2013902","journal-title":"Lancet"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-010-2678-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-010-2678-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-010-2678-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T14:05:15Z","timestamp":1560002715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-010-2678-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,23]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["2678"],"URL":"https:\/\/doi.org\/10.1007\/s00108-010-2678-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,23]]}}}